This article has Open Peer Review reports available.
Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities
© Fortner et al; licensee BioMed Central Ltd. 2004
Received: 30 January 2004
Accepted: 20 May 2004
Published: 20 May 2004
Patients with cancer must make frequent visits to the clinic not only for chemotherapy but also for the management of treatment-related adverse effects. Neutropenia, the most common dose-limiting toxicity of myelosuppressive chemotherapy, has substantial clinical and economic consequences. Colony-stimulating factors such as filgrastim and pegfilgrastim can reduce the incidence of neutropenia, but the clinic visits for these treatments can disrupt patients' routines and activities.
We surveyed patients to assess how clinic visits for treatment with chemotherapy and the management of neutropenia affect their time and activities.
The mean amounts of time affected by these visits ranged from approximately 109 hours (hospitalization for neutropenia) and 8 hours (physician and chemotherapy) to less than 3 hours (laboratory and treatment with filgrastim or pegfilgrastim). The visits for filgrastim or pegfilgrastim were comparable in length, but treatment with filgrastim requires several visits per chemotherapy cycle and treatment with pegfilgrastim requires only 1 visit.
This study provides useful information for future modelling of additional factors such as disease status and chemotherapy schedule and provides information that should be considered in managing chemotherapy-induced neutropenia.
Cancer is a devastating disease that affects patients' quality of life. The treatment of cancer also causes problems for patients, such as nausea and vomiting, anemia, and neutropenia [1–6]. Moreover, a diagnosis of cancer necessitates a large number of medical visits for monitoring the disease, treating it, and providing supportive care.
The treatment of cancer may require that patients visit an outpatient clinic numerous times over a course of months or years. Those patients who have employment often have to take time off work for long periods to be treated and have to shift many of their activities and responsibilities because of the time required for treatment. Patients spend time preparing, travelling to the clinic, waiting at the clinic, and travelling from the clinic. These visits affect their normal life activities both in the time taken away from those activities and in their associated costs, such as lost work time. In addition, there can be logistical challenges in transportation and living arrangements and disruptions of work and daily living. The stress associated with these visits can also affect their psychological outlook.
The number of medical visits that are necessary with chemotherapy treatment depends on many factors, including the type and extent of the disease and the schedule of the chemotherapy. One of the factors that can greatly affect the number of visits is chemotherapy-induced neutropenia. Chemotherapy-induced neutropenia is the most common dose-limiting toxicity of myelosuppressive chemotherapy, and it has several economic and clinical consequences . Neutropenia also puts patients at high risk for infection, and it can be life-threatening . If not managed properly, neutropenia can result in a large number of medical visits for monitoring the neutrophil counts, outpatient intravenous antibiotics, physician and nurse visits, and hospitalization .
Supportive therapies such as colony-stimulating factors (CSFs) can reduce the incidence of chemotherapy-induced neutropenia . The CSFs filgrastim and pegfilgrastim are indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies treated with myelosuppressive anticancer drugs [9, 10]. Both of these agents are effective in reducing the risks and incidence of neutropenia and its complications, but they too can affect patients' quality of life, by requiring additional medical visits.
Treatment with filgrastim can require up to 10 or more daily injections per chemotherapy cycle for its full benefits to be obtained; pegfilgrastim, however, is given only once per cycle . The clinic visits that are necessary for managing chemotherapy-induced neutropenia with CSFs can also disrupt patients' lives and create stress.
The purpose of this study was to determine the amounts of time required for medical visits in treatment with chemotherapy and to better understand the implications of the strategies for managing chemotherapy-induced neutropenia.
All study procedures were approved by the Western Institutional Review Board. The study design was a 20-site single-time-point survey of patients with cancer in community-based oncology practices. Patients were selected in a nonrandom fashion according to the inclusion criteria.
Patients were enrolled between May 2003 and July 2003. They were required to be at least 18 years old and must have been treated with primary prophylaxis with either filgrastim or pegfilgrastim 1 month before enrollment. Written informed consent was obtained from all patients, and they were not given any monetary incentives or compensations for participating in the study.
Physician and chemotherapy visit
Nurse practitioner visit
Patient demographics (N = 189)
Age, y, mean (SD)
Asian or Pacific Island
Native American or Alaska Native
Unemployed, looking for work
Less than high school
Some high school
High school diploma
Some graduate school
Annual household income, US$
Prefer not to say
Effects on patients
This study shows that, from the point of view of the patient, there is no such thing as a short clinic visit. As expected, patient time was affected most by neutropenia-related hospitalizations, but even visits for relatively simple procedures, such as laboratory draws, take a lot of time. Clinic visits for these purposes cause patients to deviate from their normal activities and prevent them from pursuing their normal life activities.
This study looked at patient time and life activities that were affected before and after the actual visit, as well as the time of the visit itself. Lindley and colleagues also reported that patient time was affected after a visit in addition to the visit itself . For example, rescheduling trips or extending work activities can result in a large amount of time being affected by medical visits. Meehan and colleagues found that the average time spent travelling to a clinic was 40 minutes . The time spent travelling for treatment can be a potential barrier to patients' seeking treatment and keeping their medical appointments. Patients must have reliable transportation , which can be difficult if they have limited access to transportation or if long distances are involved [15, 16]. Transportation can be especially problematic if the patient cannot drive, does not have a car, or uses a wheelchair . Public transportation is often unreliable and time-consuming. Patients also often make alternative living arrangements so that they can have better access to a caregiver or to the clinic . The effects of travelling to the clinic can be so great that impaired access to transportation may cause patients to forgo treatment [17, 18].
In addition to the logistical inconveniences and economic hardships of travel , it can be another source of stress and can have negative psychological effects on patients . This stress could even affect their willingness to undergo further treatment . Worrying about going to the clinic decreases patients' energy levels and functionality for daily activities. Patients' stress, anxiety, and depression may increase, especially if they do not understand why they must visit the clinic numerous times. Managing this stress can improve patients' well-being .
In addition to the costs associated with travelling to the clinic [15, 16], the costs associated with lost work time may be an economic burden for patients . Overnight accommodations may be required, and out-of-pocket expenses can be substantial. Patients often have little or no insurance coverage for out-of-pocket or incidental expenses such as lodging, gas, and meals [14, 21, 22]. Meehan and colleagues reported that not only were clinic visits time-consuming and inconvenient for both patients and their caregivers, but they also generated no reimbursable costs . Other studies have also found that transportation is the largest out-of-pocket expense for treatment, followed by meals [21, 23].
In addition to time, each clinic visit affects several life activities, which results in patients' changing, postponing, or cancelling those activities. At least 1 life activity was affected by each type of medical visit. As expected, the medical visit that accounted for the most time, neutropenia-related hospitalization, also affected more life activities than the other types of visits.
The time that was required for a single visit for treatment with filgrastim was the same as that for a visit for treatment with pegfilgrastim, but treatment with filgrastim requires several daily visits during a cycle of chemotherapy and treatment with pegfilgrastim requires only 1 visit. If patients are given 10 daily injections of filgrastim, which may be necessary for their ANC to reach the recommended 10 × 109/L , the time required would be 24 hours, whereas equivalent treatment with pegfilgrastim would take less than 3 hours.
Patient care can be optimized by reducing the number of clinic visits. Nurses play a central role in minimizing the disruptions that treatment has on the lives of patients and their families and caregivers, and patients often perceive nurses as being a liaison between themselves and their physicians . Nurses can educate and instruct patients on how to manage their symptoms, such as what symptoms to report and how and when to take their temperature. Implementing protocols and guidelines can improve the management of neutropenia and can help nurses conduct patient assessments more efficiently [24, 25]. Telephone triage in particular can be effective, convenient, and practical, by helping determine which patients should be seen frequently and which patients can be managed by telephone .
The choice of the treatment can also help reduce the number of clinic visits. Moore and colleagues reported that the amount of time actually spent at the clinic may be inconsequential, because patients still have to interrupt their routines to go to the clinic . The CSF used to manage neutropenia can be important and can affect the number of clinic visits and amount of patient time. Decreasing the number of clinic visits can have a positive effect on patients by improving their functional [2, 3, 21], social [2, 21], and financial well-being [14, 21, 23], in addition to decreasing their emotional stress [1, 14, 27]. The greater convenience of fewer clinic visits could also increase patient adherence and lessen the likelihood that patients might put themselves at greater risk for neutropenia by not going to the clinic for their treatment.
This study provides new data on how medical visits affect patients. It is clear that treatment with chemotherapy – as well as the management of adverse events – involves a great number of medical visits and that these visits have substantial effects on patient time and activities. The study is based solely on patient self-reports, however, and the extent to which patients can accurately recall this type of information is not certain. Future studies might use other methods, such as prospective observation or patient diaries, to confirm and extend these findings.
- Ashley J, Taylor D, Houts A, Fortner B, Durrence H: The experience of chemotherapy-induced neutropenia: quality-of-life interviews with adult cancer patients [abstract]. Oncol Nurs Forum. 2003, 30: 120-Google Scholar
- Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D: Changing patient perceptions of the side effects of cancer chemotherapy. Cancer. 2002, 95: 155-163. 10.1002/cncr.10630.View ArticlePubMedGoogle Scholar
- Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997, 34 (3 Suppl 2): 13-19.PubMedGoogle Scholar
- Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vozelgang NJ: Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000, 5: 353-360.View ArticlePubMedGoogle Scholar
- Houston D: Supportive therapies for cancer chemotherapy patients and the role of the oncology nurse. Cancer Nurs. 1997, 20: 409-413. 10.1097/00002820-199712000-00004.View ArticlePubMedGoogle Scholar
- Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E: Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage . 1997, 13: 63-74. 10.1016/S0885-3924(96)00274-6.View ArticlePubMedGoogle Scholar
- Crawford J, Dale DC, Lyman GH: Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004, 100: 228-237. 10.1002/cncr.11882.View ArticlePubMedGoogle Scholar
- Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri JD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Somerfield MR: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000, 18: 3558-3585.PubMedGoogle Scholar
- Neupogen (filgrastim) prescribing information. 2002, Thousand Oaks, Calif: AmgenGoogle Scholar
- Neulasta (pegfilgrastim) prescribing information. 2002, Thousand Oaks, Calif: AmgenGoogle Scholar
- Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart M: A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003, 14: 29-35. 10.1093/annonc/mdg019.View ArticlePubMedGoogle Scholar
- Lindley C, Vasa S, Sawyer WT, Winer EP: Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol. 1998, 16: 1380-1387.PubMedGoogle Scholar
- Meehan K, Tchekmedyian S, Ciesla G, Kallich J, Erder MH, Smith R: The burden of weekly epoetin alfa injections to patients and their caregivers [abstract]. Proc Am Soc Clin Oncol. 2003, 22: 543-Google Scholar
- Moore K, Fortner B, Okon T: The impact of medical visits on patients with cancer [abstract]. Oncol Nurs Forum. 2003, 30: 128-View ArticleGoogle Scholar
- Hinds G, Moyer A: Support as experienced by patients with cancer during radiotherapy treatments. J Adv Nurs. 1997, 26: 371-379. 10.1046/j.1365-2648.1997.1997026371.x.View ArticlePubMedGoogle Scholar
- Junor EJ, Macbeth FR, Barrett A: An audit of travel and waiting times for outpatient radiotherapy. Clin Oncol (R Coll Radiol). 1992, 4: 174-176.View ArticleGoogle Scholar
- Goodwin JS, Hunt WC, Samet JM: Determinants of cancer therapy in elderly patients. Cancer. 1993, 72: 594-601.View ArticlePubMedGoogle Scholar
- Guidry JJ, Aday LA, Zhang D, Winn RJ: Transportation as a barrier to cancer treatment. Cancer Practice. 1997, 5: 361-366.PubMedGoogle Scholar
- Payne S, Jarrett N, Jeffs D: The impact of travel on cancer patients' experiences of treatment: a literature review. Eur J Cancer Care. 2000, 9: 197-203. 10.1046/j.1365-2354.2000.00225.x.View ArticleGoogle Scholar
- Jacobsen PB, Meade CD, Stein KD, Chirikos TN, Small BJ, Ruckdeschel JC: Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy. J Clin Oncol. 2002, 20: 2851-2862. 10.1200/JCO.2002.08.301.View ArticlePubMedGoogle Scholar
- Moore KA: Breast cancer patients' out-of-pocket expenses. Cancer Nurs. 1999, 22: 389-396. 10.1097/00002820-199910000-00007.View ArticlePubMedGoogle Scholar
- Pearce S, Kelly D, Stevens W: 'More than just money' – widening the understanding of the costs involved in cancer care. J Adv Nurs . 2001, 33: 371-379. 10.1046/j.1365-2648.2001.01673.x.View ArticlePubMedGoogle Scholar
- Houts PS, Lipton A, Harvey HA, Martin B, Simmonds MA, Dixon RH, Longo S, Andrews T, Gordon RA, Meloy J: Nonmedical costs to patients and their families associated with outpatient chemotherapy. Cancer. 1984, 53: 2388-2392.View ArticlePubMedGoogle Scholar
- Glynn-Tucker EM: A multidisciplinary performance improvement project for the management of febrile neutropenia [abstract]. Oncol Nurs Forum. 2002, 29: 354-Google Scholar
- Maxwell C, Winkler L, Lottenberg M: Nurse driven neutropenia management guidelines: improving patient outcomes through evidence-based practice [abstract]. Oncol Nurs Forum. 2002, 29: 371-Google Scholar
- Anastasia PJ, Blevins MC: Outpatient chemotherapy: telephone triage for symptom management. Oncol Nurs Forum. 1997, 24 (1 Suppl): 13-22.PubMedGoogle Scholar
- Kallich JD, Tchekmedyian NS, Damiano AM, Shi J, Black JT, Erder MH: Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Huntingt). 2002, 16 (9 Suppl 10): 117-124.Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/4/22/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.